These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36437872)

  • 1. The
    Bikorimana JP; El-Hachem N; Abusarah J; Eliopoulos N; Talbot S; Shammaa R; Rafei M
    iScience; 2022 Dec; 25(12):105537. PubMed ID: 36437872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humoral Immunity to Allogeneic Immunoproteasome-Expressing Mesenchymal Stromal Cells Requires Efferocytosis by Endogenous Phagocytes.
    Bikorimana JP; Abusarah J; Salame N; El-Hachem N; Shammaa R; Rafei M
    Cells; 2022 Feb; 11(4):. PubMed ID: 35203247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thymoproteasome-Expressing Mesenchymal Stromal Cells Confer Protective Anti-Tumor Immunity
    Bikorimana JP; El-Hachem N; El-Kadiry AE; Abusarah J; Salame N; Shammaa R; Rafei M
    Front Immunol; 2020; 11():596303. PubMed ID: 33542714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint.
    Voets E; Paradé M; Lutje Hulsik D; Spijkers S; Janssen W; Rens J; Reinieren-Beeren I; van den Tillaart G; van Duijnhoven S; Driessen L; Habraken M; van Zandvoort P; Kreijtz J; Vink P; van Elsas A; van Eenennaam H
    J Immunother Cancer; 2019 Dec; 7(1):340. PubMed ID: 31801627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. UM171A-induced ROS promote antigen cross-presentation of immunogenic peptides by bone marrow-derived mesenchymal stromal cells.
    Salame N; Bikorimana JP; El-Hachem N; Saad W; Kurdi M; Zhao J; Eliopoulos N; Shammaa R; Rafei M
    Stem Cell Res Ther; 2022 Jan; 13(1):16. PubMed ID: 35012668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A1-reprogrammed mesenchymal stromal cells prime potent antitumoral responses.
    Gonçalves MP; Farah R; Bikorimana JP; Abusarah J; El-Hachem N; Saad W; Talbot S; Stanga D; Beaudoin S; Plouffe S; Rafei M
    iScience; 2024 Mar; 27(3):109248. PubMed ID: 38433914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer immunotherapy targeting the CD47/SIRPα axis.
    Weiskopf K
    Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
    Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
    J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
    Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
    Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity.
    de Silva S; Fromm G; Shuptrine CW; Johannes K; Patel A; Yoo KJ; Huang K; Schreiber TH
    Cancer Immunol Res; 2020 Feb; 8(2):230-245. PubMed ID: 31852716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD47/SIRPα axis: bridging innate and adaptive immunity.
    van Duijn A; Van der Burg SH; Scheeren FA
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35831032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Versatile activatable vSIRPα-probe for cancer-targeted imaging and macrophage-mediated phagocytosis of cancer cells.
    Ko YJ; Lee JW; Kim H; Cho E; Yang Y; Kim IS; Kim SH; Kwon IC
    J Control Release; 2020 Jul; 323():376-386. PubMed ID: 32335154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer.
    Hsieh RC; Krishnan S; Wu RC; Boda AR; Liu A; Winkler M; Hsu WH; Lin SH; Hung MC; Chan LC; Bhanu KR; Srinivasamani A; De Azevedo RA; Chou YC; DePinho RA; Gubin M; Vilar E; Chen CH; Slay R; Jayaprakash P; Hegde SM; Hartley G; Lea ST; Prasad R; Morrow B; Couillault CA; Steiner M; Wang CC; Venkatesulu BP; Taniguchi C; Kim YSB; Chen J; Rudqvist NP; Curran MA
    Sci Immunol; 2022 Jun; 7(72):eabl9330. PubMed ID: 35687697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis.
    Ho CC; Guo N; Sockolosky JT; Ring AM; Weiskopf K; Özkan E; Mori Y; Weissman IL; Garcia KC
    J Biol Chem; 2015 May; 290(20):12650-63. PubMed ID: 25837251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD47/SIRPα pathway mediates cancer immune escape and immunotherapy.
    Jia X; Yan B; Tian X; Liu Q; Jin J; Shi J; Hou Y
    Int J Biol Sci; 2021; 17(13):3281-3287. PubMed ID: 34512146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity.
    Cendrowicz E; Jacob L; Greenwald S; Tamir A; Pecker I; Tabakman R; Ghantous L; Tamir L; Kahn R; Avichzer J; Aronin A; Amsili S; Zorde-Khvalevsky E; Gozlan Y; Vlaming M; Huls G; van Meerten T; Dranitzki ME; Foley-Comer A; Pereg Y; Peled A; Chajut A; Bremer E
    J Exp Clin Cancer Res; 2022 Mar; 41(1):97. PubMed ID: 35287686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding.
    Puro RJ; Bouchlaka MN; Hiebsch RR; Capoccia BJ; Donio MJ; Manning PT; Frazier WA; Karr RW; Pereira DS
    Mol Cancer Ther; 2020 Mar; 19(3):835-846. PubMed ID: 31879362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promoting antigen escape from dendritic cell endosomes potentiates anti-tumoral immunity.
    Bikorimana JP; Salame N; Beaudoin S; Balood M; Crosson T; Abusarah J; Talbot S; Löbenberg R; Plouffe S; Rafei M
    Cell Rep Med; 2022 Mar; 3(3):100534. PubMed ID: 35492876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells.
    Tahk S; Vick B; Hiller B; Schmitt S; Marcinek A; Perini ED; Leutbecher A; Augsberger C; Reischer A; Tast B; Humpe A; Jeremias I; Subklewe M; Fenn NC; Hopfner KP
    J Hematol Oncol; 2021 Sep; 14(1):155. PubMed ID: 34579739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel SIRPα Antibodies That Induce Single-Agent Phagocytosis of Tumor Cells while Preserving T Cells.
    Andrejeva G; Capoccia BJ; Hiebsch RR; Donio MJ; Darwech IM; Puro RJ; Pereira DS
    J Immunol; 2021 Feb; 206(4):712-721. PubMed ID: 33431660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.